[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Wassmann B, Klein SA, Scheuring U, Pfeifer H, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG: Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant; 2001 Oct;28(7):721-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
  • We describe the clinical activity of the ABL kinase inhibitor STI571 in a patient with accelerated phase of chronic myeloid leukemia (CML) relapsing after a second allogeneic BMT and with minimal levels of donor chimerism.
  • STI571 induced sustained hematological and cytogenetic remission combined with controllable GvHD, therapeutic goals not achieved by two preceding allogeneic transplants and repeated donor lymphocyte transfusions (DLT).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Accelerated Phase / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Salvage Therapy
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Benzamides. Colitis / chemically induced. Combined Modality Therapy. Enzyme Inhibitors / adverse effects. Enzyme Inhibitors / therapeutic use. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Leukemia Effect. Humans. Hydroxyurea / therapeutic use. Imatinib Mesylate. Immunosuppression. Interferon-alpha / therapeutic use. Leukemia, Myeloid, Chronic-Phase / drug therapy. Leukemia, Myeloid, Chronic-Phase / therapy. Lymphocyte Transfusion. Middle Aged. Neoplasm, Residual. Neutropenia / chemically induced. Remission Induction. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11704799.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Interferon-alpha; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


2. Serrano J, Prieto E, Mazarbeitia F, Román A, Llamas P, Tomás JF: Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT. Bone Marrow Transplant; 2001 Jan;27(1):85-7
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT.
  • We report a 54-year-old woman who received interferon alpha for haematological relapse of Ph-positive CML, 7 years after allogeneic BMT from an HLA-identical brother.
  • Eighteen months after relapse, cytogenetic and molecular remission was achieved.
  • She received interferon therapy for 25 months and it was discontinued when she developed skin lesions on her face and trunk, dysphagia and fever with respiratory failure and bilateral patchy airspace consolidation of the lung without microbiologic findings.
  • Histologic features showed discoid lupus erythematosis, oesophagitis with pseudomembranes and a mixed pattern of lymphocytic bronchiolitis involving the alveoli and interstitial spaces all compatible with chronic GVHD.
  • The patient was commenced on immunosuppressive therapy with complete clinical and radiological resolution.
  • The available evidence supports an atypical presentation of chronic GVHD and suggests a role for interferon alpha in the pathogenesis of GVHD.
  • To the best of our knowledge, this is the first case reported of severe chronic GVHD occurring during the course of interferon therapy for relapsed CML.
  • [MeSH-major] Graft vs Host Disease / chemically induced. Interferon-alpha / toxicity. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / toxicity. Bone Marrow Transplantation. Chronic Disease. Female. Humans. Middle Aged. Recurrence. Transplantation, Homologous

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11244442.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


3. DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ: Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res; 2004 Aug 1;10(15):5065-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
  • PURPOSE: Over the last several years, donor lymphocyte infusions have become the standard approach for patients with chronic myelogenous leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT).
  • EXPERIMENTAL DESIGN: We studied 15 patients treated with imatinib for recurrent CML after SCT, 10 patients with stable phase CML (SP-CML), 1 with accelerated phase (AP-CML), and 4 with blast phase (BP-CML).
  • RESULTS: Of the 10 patients with SP-CML, all achieved a hematological response.
  • The BCR-ABL transcript could not be detected by reverse transcription-PCR in 7 of these 9 patients.
  • No patient developed graft-versus-host disease.
  • Only one of the 5 patients with AP/BP-CML achieved a complete cytogenetic response.
  • CONCLUSIONS: We find that imatinib is well tolerated in patients with SP-CML who relapse after SCT.
  • Imantinib was far less effective in patients who relapsed with AP/BP-CML.
  • Imatinib should be evaluated as either an alternative or as an adjunct to donor lymphocyte infusions for patients with SP-CML who relapse after SCT.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Cytogenetics. Female. Fusion Proteins, bcr-abl / biosynthesis. Graft vs Host Disease / prevention & control. Humans. Imatinib Mesylate. Male. Middle Aged. Protein Kinase Inhibitors / therapeutic use. Recurrence. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Stem Cell Transplantation / methods. Time Factors. Transplantation Chimera. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297408.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


Advertisement
4. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ: A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica; 2006 May;91(5):663-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
  • Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT).
  • The outcome of CML patients transplanted at our center who had received only imatinib for relapse after HSCT was compared with that of patients treated with donor lymphocyte infusions (DLI).
  • Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively).
  • These data suggest that imatinib alone probably does not cure relapse after HSCT.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphocyte Transfusion. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adult. Benzamides. Biomarkers, Tumor / biosynthesis. Disease-Free Survival. Female. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / biosynthesis. Humans. Imatinib Mesylate. Leukemia, Myeloid, Accelerated Phase / surgery. Leukemia, Myeloid, Chronic-Phase / surgery. Living Donors. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627251.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


5. Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K: NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant; 2010 Nov;16(11):1467-503
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
  • Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT).
  • Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease.
  • There is no standard approach to treating relapse after alloHSCT.
  • Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies.
  • Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective.
  • As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT.
  • This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner.
  • In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.
  • [MeSH-major] Hematologic Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Hodgkin Disease / therapy. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Lymphocyte Transfusion. Lymphoma, Non-Hodgkin. Multiple Myeloma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Recurrence. Transplantation, Homologous. Treatment Failure

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. All rights reserved.
  • [Cites] Bone Marrow Transplant. 1997 May;19(10):977-82 [9169641.001]
  • [Cites] Leukemia. 1997 May;11(5):729-31 [9180299.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1664-72 [9269787.001]
  • [Cites] Rinsho Ketsueki. 1997 Aug;38(8):643-6 [9311269.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2549-54 [9326220.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4206-11 [9354693.001]
  • [Cites] J Immunol. 1997 Dec 15;159(12):5921-30 [9550389.001]
  • [Cites] Blood. 1998 May 15;91(10):3671-80 [9573003.001]
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):301-13 [9684928.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):639-43 [9818690.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1201-8 [10438707.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):208-15 [10458235.001]
  • [Cites] Biol Blood Marrow Transplant. 1999;5(4):253-61 [10465105.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3361-3 [15292062.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3797-803 [15280203.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] J Exp Med. 2004 Dec 20;200(12):1623-33 [15611290.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(2):165-9 [15531895.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):496-502 [15686458.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • [Cites] Leukemia. 2003 May;17(5):841-8 [12750695.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1035-7 [12764364.001]
  • [Cites] Bone Marrow Transplant. 2003 Jun;31(11):973-9 [12774047.001]
  • [Cites] Blood. 2003 Jul 15;102(2):442-8 [12560224.001]
  • [Cites] Blood. 2003 Jul 15;102(2):571-6 [12576330.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2747-53 [12860954.001]
  • [Cites] Exp Hematol. 2003 Sep;31(9):743-51 [12962719.001]
  • [Cites] Ann Hematol. 2003 Sep;82(9):548-51 [14504811.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):835-42 [14520431.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:331-49 [14633789.001]
  • [Cites] Bone Marrow Transplant. 2003 Dec;32(12):1159-63 [14647270.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] Leukemia. 2004 Jan;18(1):165-6 [14603333.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):28-35 [14725898.001]
  • [Cites] Blood. 2004 Feb 1;103(3):790-5 [14525766.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Hematol J. 2004;5(1):47-54 [14745430.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1548-56 [14576063.001]
  • [Cites] Transplantation. 2004 Feb 15;77(3):391-8 [14966413.001]
  • [Cites] Leukemia. 2004 Mar;18(3):659-62 [14671630.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12 [14993886.001]
  • [Cites] Rinsho Ketsueki. 2004 Feb;45(2):155-60 [15045825.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1696-705 [15117992.001]
  • [Cites] Blood. 2004 May 15;103(10):3982-5 [14764538.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4362-4 [14976044.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):731-3 [15160947.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5 [15148407.001]
  • [Cites] Exp Hematol. 2004 Jun;32(6):556-62 [15183896.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2583-91 [15197800.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(2):123-8 [15133487.001]
  • [Cites] Semin Hematol. 2004 Jul;41(3):201-6 [15269880.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(5):391-7 [15273707.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Sep;10(9):579-90 [15319770.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1557-8 [15229619.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]
  • [Cites] Bone Marrow Transplant. 2004 Oct;34(8):721-7 [15322568.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1103-12 [17023585.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Transfusion. 2007 Mar;47(3):520-8 [17319835.001]
  • [Cites] Haematologica. 2007 Mar;92(3):414-7 [17339194.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3588-94 [17158231.001]
  • [Cites] Mol Ther. 2007 May;15(5):981-8 [17375070.001]
  • [Cites] Clin Exp Immunol. 2007 Jun;148(3):520-8 [17493020.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5489-97 [17545631.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] Br J Haematol. 2007 Oct;139(1):70-80 [17854309.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2620-30 [17507664.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2761-3 [17579184.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2744-8 [17595333.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1160-8 [17889352.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2838-45 [17609424.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):1931-9 [17917961.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Vaccine. 2007 Nov 14;25(46):7955-61 [17933439.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2600-2 [15205268.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 [15381769.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1789-97 [15385924.001]
  • [Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]
  • [Cites] Lancet. 1978 Sep 9;2(8089):537-40 [79913.001]
  • [Cites] N Engl J Med. 1979 May 10;300(19):1068-73 [34792.001]
  • [Cites] Am J Pathol. 1987 Oct;129(1):86-91 [2821817.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):50-7 [2642540.001]
  • [Cites] Br J Haematol. 1988 Nov;70(3):317-20 [3061443.001]
  • [Cites] Bone Marrow Transplant. 1988 Nov;3(6):619-24 [3063329.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • [Cites] Blood. 1991 Feb 1;77(3):649-53 [1991174.001]
  • [Cites] Blood. 1991 Apr 1;77(7):1423-8 [2009366.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4766-70 [1647016.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1162-5 [1652308.001]
  • [Cites] Bone Marrow Transplant. 1992 Oct;10(4):391-5 [1422499.001]
  • [Cites] Bone Marrow Transplant. 1993 Feb;11(2):109-11 [8435660.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2342-50 [8246023.001]
  • [Cites] N Engl J Med. 1994 Jan 13;330(2):100-6 [8259165.001]
  • [Cites] N Engl J Med. 1994 Nov 10;331(19):1253-8 [7935682.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3983 [7949156.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3148-57 [7949187.001]
  • [Cites] Bone Marrow Transplant. 1994 Aug;14(2):331-2 [7994252.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1122-31 [7849300.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1016-20 [7723498.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1261-8 [7632930.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4337-43 [7492795.001]
  • [Cites] Exp Hematol. 1995 Dec;23(14):1553-62 [8542946.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1196-8 [8562947.001]
  • [Cites] Lancet. 1996 Mar 23;347(9004):800-1 [8622337.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):572-8 [8636773.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4609-16 [8648103.001]
  • [Cites] Blood. 1996 Jul 1;88(1):41-8 [8704200.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2787-93 [8839877.001]
  • [Cites] Clin Lab Haematol. 1996 Mar;18(1):45-6 [9118604.001]
  • [Cites] Bone Marrow Transplant. 1996 Sep;18(3):669-72 [8879640.001]
  • [Cites] Leukemia. 1997 Feb;11(2):281-3 [9009093.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] Bone Marrow Transplant. 1997 Mar;19(5):461-6 [9052912.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):165-8 [9136960.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):697-702 [9156247.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5094-100 [18711173.001]
  • [Cites] Haematologica. 2008 Nov;93(11):1702-11 [18728020.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6907-15 [18980985.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):468-80 [18710379.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5151-3 [18824700.001]
  • [Cites] Bone Marrow Transplant. 2008 Nov;42(9):569-79 [18711351.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):463-4 [18836792.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4371-83 [19029455.001]
  • [Cites] Leuk Res. 2009 Jan;33(1):174-7 [18471874.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):177-81 [18816698.001]
  • [Cites] Eur J Haematol. 2009 Jan;82(1):61-8 [18801058.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2142-50 [18818707.001]
  • [Cites] Exp Hematol. 2009 Jan;37(1):135-42 [19100523.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):426-32 [19064981.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(2):107-13 [18776928.001]
  • [Cites] Haematologica. 2009 Feb;94(2):230-8 [19066328.001]
  • [Cites] Haematologica. 2009 Feb;94(2):296-8 [19109219.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):794-5 [19036096.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1581-8 [18974373.001]
  • [Cites] Exp Hematol. 2005 Mar;33(3):286-94 [15730852.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2473-9 [15572591.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):549-56 [15756282.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1993-2003 [15774790.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2973-8 [15613541.001]
  • [Cites] Blood. 2005 May 15;105(10):3945-50 [15692072.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3433-8 [15809449.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):631-43 [15916686.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3819-29 [15809448.001]
  • [Cites] Lancet. 2005 Jun 4-10;365(9475):1934-41 [15936420.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4504-11 [15958636.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(4):315-23 [15968284.001]
  • [Cites] Bone Marrow Transplant. 2005 Sep;36(5):437-41 [15980879.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Nov;11(11):823-61 [16275588.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:292-8 [16304394.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):351-6 [16307422.001]
  • [Cites] Cancer Immunol Immunother. 2006 Feb;55(2):197-209 [16025268.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4389-96 [16131571.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8 [16344099.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83 [16443515.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1724-30 [16239425.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1325-31 [16269610.001]
  • [Cites] Leukemia. 2006 Mar;20(3):542-5 [16408097.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):414-21 [16545725.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1575-81 [16520464.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3415-6 [16597603.001]
  • [Cites] Blood. 2006 May 1;107(9):3804-7 [16384924.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4563-9 [16449533.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1040-6 [16525495.001]
  • [Cites] Exp Hematol. 2006 Jun;34(6):770-5 [16728282.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1135-41 [16757975.001]
  • [Cites] Haematologica. 2006 Jun;91(6 Suppl):ECR16 [16785122.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):978-85 [16840186.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):737-55 [16997180.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1754-67 [17064985.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64 [17084369.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1653-61 [17145602.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2079-86 [10602432.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1214-21 [10666193.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1572-9 [10688810.001]
  • [Cites] Br J Haematol. 2000 Feb;108(2):400-7 [10691873.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):221-34 [10830730.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2273-81 [10829048.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3):272-9 [10871152.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3A):321-6 [10905769.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2712-6 [11023502.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):1013-4 [11054097.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(11):1179-84 [11149728.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):421-3 [11167841.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Blood. 2001 Jul 1;98(1):210-6 [11418482.001]
  • [Cites] Blood. 2001 Aug 15;98(4):934-9 [11493435.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3675-84 [11504749.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4314-21 [11731514.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):405-12 [11786567.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4938-45 [17909197.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):824-31 [18021093.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1533-48 [18024402.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2569-74 [17611558.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2540-4 [17611563.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2452-5 [17728782.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):847-54 [18049337.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):61-70 [18075512.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):50-8 [18158961.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1594-602 [18032710.001]
  • [Cites] Haematologica. 2008 Feb;93(2):257-64 [18223284.001]
  • [Cites] Haematologica. 2008 Feb;93(2):303-6 [18245655.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Haematologica. 2008 Mar;93(3):455-8 [18287132.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):495-503 [17952130.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):483-93 [18026156.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25 [18342784.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Apr;14(4):480-3 [18342792.001]
  • [Cites] Br J Haematol. 2008 Apr;141(2):235-43 [18318762.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4392-402 [17878399.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):779-84 [18195681.001]
  • [Cites] Leukemia. 2008 May;22(5):1007-17 [18323802.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2519-25 [18427150.001]
  • [Cites] Clin Immunol. 2008 Jun;127(3):280-5 [18337174.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):817-23 [18541202.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5530-6 [18411419.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1377-86 [18418404.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42(3):201-5 [18490913.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42(3):145-57 [18587431.001]
  • [Cites] Science. 2008 Aug 15;321(5891):974-7 [18703743.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1876-85 [18591381.001]
  • [Cites] Cancer Immunol Immunother. 2008 Nov;57(11):1705-10 [18663443.001]
  • [Cites] Br J Haematol. 2008 Sep;142(5):848-50 [18631344.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3500-7 [18664621.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97 [18940684.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3574-81 [18606875.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1935-40 [18684698.001]
  • [Cites] J Clin Immunol. 2002 May;22(3):124-30 [12078853.001]
  • [Cites] Blood. 2002 Jul 15;100(2):397-405 [12091328.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3108-14 [12384406.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3121-7 [12384408.001]
  • [Cites] Curr Opin Hematol. 2002 Nov;9(6):503-8 [12394172.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(11):625-32 [12463482.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):36-8 [12517774.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):523-5 [12580972.001]
  • [Cites] Leukemia. 2003 Feb;17(2):468-70 [12592351.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):157-61 [12621475.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1278-84 [12663715.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Apr;25(4):327-9 [12679650.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65 [12720218.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(9):739-46 [12732878.001]
  • [Cites] Bone Marrow Transplant. 2009 Feb;43(4):327-33 [18850014.001]
  • [Cites] Leukemia. 2009 Mar;23(3):605-7 [18784738.001]
  • [Cites] Bone Marrow Transplant. 2009 Mar;43(5):383-97 [18850012.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1492-501 [19224851.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 May;15(5):580-8 [19361750.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 May;15(5):610-7 [19361753.001]
  • [Cites] Leuk Lymphoma. 2009 Apr;50(4):551-8 [19373652.001]
  • [Cites] Cancer. 2009 May 1;115(9):1899-905 [19235255.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4144-52 [19168784.001]
  • [Cites] Leuk Res. 2009 Jul;33(7):e61-3 [19157550.001]
  • [Cites] Curr Opin Hematol. 2009 Mar;16(2):112-23 [19468273.001]
  • [Cites] Bone Marrow Transplant. 2009 Jun;43(11):839-43 [19151791.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6567-71 [19389879.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):478-88 [19641204.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1429-36 [19528536.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3951-8 [19620487.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15825-30 [19717467.001]
  • [Cites] Bone Marrow Transplant. 2009 Nov;44(9):585-8 [19363531.001]
  • [Cites] Eur J Clin Invest. 2009 Dec;39(12):1098-109 [19744184.001]
  • [Cites] Leuk Lymphoma. 2009 Aug;50(8):1239-48 [19562639.001]
  • [Cites] Cancer. 2009 Dec 1;115(23):5490-8 [19708032.001]
  • [Cites] Cancer Treat Rev. 2009 Dec;35(8):653-61 [19682801.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):6012-8 [19826119.001]
  • [Cites] Leuk Lymphoma. 2009 Dec;50(12):2075-7 [19637088.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85 [19744569.001]
  • [Cites] Bone Marrow Transplant. 2010 Feb;45(2):349-53 [19584825.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Mar;16(3):301-10 [19744571.001]
  • [Cites] Bone Marrow Transplant. 2010 Mar;45(3):558-64 [19633691.001]
  • [Cites] Clin Cancer Res. 2010 Mar 15;16(6):1894-903 [20215554.001]
  • [Cites] Mol Ther. 2010 Apr;18(4):843-51 [20179677.001]
  • [Cites] Mol Ther. 2010 Apr;18(4):666-8 [20357779.001]
  • [Cites] Bone Marrow Transplant. 2010 Apr;45(4):627-32 [19718057.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 May;16(5):639-46 [20005967.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28 [20227509.001]
  • [Cites] Blood. 2010 May 13;115(19):3869-78 [20071660.001]
  • [Cites] Cancer Res. 2010 May 15;70(10):3915-24 [20424114.001]
  • [Cites] Br J Haematol. 2010 Aug;150(3):352-8 [20528877.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1237-44 [20302960.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1187-211 [20558311.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Oct;16(10):1325-46 [20637879.001]
  • [Cites] Blood. 2010 Oct 7;116(14):2438-47 [20595516.001]
  • [Cites] Blood. 2010 Nov 11;116(19):3875-86 [20631379.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):376-89 [20141428.001]
  • (PMID = 20699125.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA117879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS241037; NLM/ PMC2955517
  •  go-up   go-down


6. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood; 2006 Feb 15;107(4):1325-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Donor lymphocyte infusions (DLIs) induce potent graft versus tumor (GVT) effects for relapsed chronic myelogenous leukemia (CML) after allogeneic stem cell transplantation (SCT) but are disappointing for other diseases.
  • We performed a phase 1 trial of ex vivo-activated DLI (aDLI) for 18 patients with relapse after SCT.
  • Patients with aggressive malignancies received induction chemotherapy, and all patients received conventional DLI (median, 1.5 x 10(8) mononuclear cells/kg) followed 12 days later by aDLI.
  • Seven patients developed acute graft versus host disease (GVHD) (5 grade I-II, 2 grade III), and 4 developed chronic GVHD.
  • Eight patients achieved complete remission, including 4 of 7 with acute lymphocytic leukemia (ALL), 2 of 4 with acute myelogenous leukemia (AML), 1 with chronic lymphocytic leukemia (CLL), and 1 of 2 with non-Hodgkin lymphoma (NHL).
  • Four complete responders relapsed while 4 remain alive in remission a median 23 months after aDLI.
  • [MeSH-major] Antigens, CD28 / blood. Antigens, CD8 / blood. Leukemia / therapy. Lymphocyte Transfusion / adverse effects. Lymphoma / therapy. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269610.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, CD8
  •  go-up   go-down


7. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ: Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant; 2005 Dec;36(11):1009-15
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
  • Donor lymphocyte infusions (DLI) have been the mainstay of treatment for chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (allo-SCT).
  • However, advanced phase relapse (APRel) responds poorly with either treatment.
  • To test the possibility that combinations of DLI and IM might be more effective, 37 patients with CML relapsing after allo-SCT between August 1994 and May 2004 were studied.
  • Ten had molecular relapse (MRel), 14 hematological relapse (HRel) and 13 APRel.
  • Thirty (81%) patients responded (actuarial survival and current leukemia-free survival of 80.6 +/- 6.7% and 69.1 +/- 7.7%).
  • Of 30 patients, 26 are in molecular remission (MR), median follow-up of 1,226 days (range 249-3257) since relapse.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphocyte Transfusion. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Drug Synergism. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Recurrence. Remission Induction / methods. Retrospective Studies. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205732.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


8. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T, Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT): Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia; 2003 Sep;17(9):1707-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
  • We studied 128 patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (SCT).
  • Disease at the time of treatment with Imatinib was in chronic phase (CP) in 51 patients, accelerated phase (AP) in 31 and blastic crisis (BC) in 46.
  • The median interval between relapse and Imatinib therapy was 5 months (0-65).
  • A total of 50 patients had failed treatment with donor lymphocyte infusions prior to Imatinib.
  • The overall hemato-logical response rate was 84% (98% for patients relapsing in CP).
  • We conclude that Imatinib has significant activity against CML in relapse after allogeneic SCT.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Female. Graft vs Leukemia Effect. Humans. Imatinib Mesylate. Male. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Transplantation, Homologous. Treatment Outcome


9. Sao H, Kato C, Kitaori K, Adachi T, Yano K, Kobayashi M, Kojima H, Tanimoto M, Hirabayashi N, Minami S, Yamada H, Morishita GY, Morishima Y, Kodera Y: Effective and safe interferon treatment for Japanese patients with chronic myelogenous leukemia relapse after bone marrow transplantation. The Nagoya Blood and Marrow Transplantation Group. Int J Hematol; 2000 Aug;72(2):237-42
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective and safe interferon treatment for Japanese patients with chronic myelogenous leukemia relapse after bone marrow transplantation. The Nagoya Blood and Marrow Transplantation Group.
  • The purpose of this study was to assess the efficacy and safety of interferon (IFN) treatment in patients with a relapse of chronic myelogenous leukemia (CML) after bone marrow transplantation in Japan.
  • One of 3 patients with hematologic relapse and all 5 patients with cytogenetic relapse achieved complete cytogenetic response (CCR).
  • The median time to achieve CCR was 8 months (range, 3-16 months).
  • One patient relapsed 9 months after starting IFN and died of blast crisis.
  • At the time of this report, 2 patients who did not attain CCR have survived for 81 months and 142 months after starting IFN, respectively.
  • During IFN treatment, 1 patient showed a transient deterioration of chronic graft-versus-host disease, and no treatment-related deaths were observed.
  • These results suggest that treatment with IFN for CML patients who relapse after bone marrow transplantation is effective and safe.
  • A prospective study to compare IFN with donor lymphocyte infusion is necessary to establish the optimal strategy for the treatment of CML patients who relapse after bone marrow transplantation.
  • [MeSH-major] Bone Marrow Transplantation. Interferons / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adult. Cytogenetic Analysis. Disease-Free Survival. Drug Evaluation. Female. Follow-Up Studies. Graft vs Host Disease. Humans. Male. Recurrence. Retrospective Studies. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11039675.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 9008-11-1 / Interferons
  •  go-up   go-down


10. Grigg A, Kannan K, Schwarer AP, Spencer A, Szer J: Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation. Intern Med J; 2001 Jan-Feb;31(1):15-22
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
  • This property may also be used to enhance a graft-versus-leukaemia effect (GVL) after donor leucocyte infusion (DLI), a mode of therapy increasingly offered to patients relapsing after allo BMT.
  • AIM: The aims of the present study were to examine the efficacy and toxicity of IFN therapy administered after granulocyte colony-stimulating factor (G-CSF)-stimulated blood cells given as DLI in patients with acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), acute lymphoblastic leukaemia (ALL), acute undifferentiated leukaemia (AUL) and multiple myeloma relapsing after allo BMT.
  • METHODS: Between October 1996 and September 1999, 27 patients (16 AML, four ALL, three CML, three multiple myeloma, one AUL) who relapsed after allo BMT were treated with chemotherapy followed by DLI, collected after G-CSF stimulation in all but two cases.
  • RESULTS: Eighteen patients received IFN following DLI, 14 of whom developed significant GVHD (grade II-IV acute or extensive chronic); thereafter, GVHD resolved with cessation of IFN alone in four patients, but 10 required systemic immunosuppression.
  • Twenty-three patients were given chemotherapy and DLI as initial treatment of relapse; 10 achieved complete remission (CR), in four patients this was only after the onset of GVHD.
  • The other four patients received chemotherapy and DLI as a consolidation of a chemotherapy-induced remission.
  • The CR was durable only in patients with CML (3 of 3) and AML (4 of 8).
  • CONCLUSIONS: Treatment with IFN induced GVHD in the majority of patients receiving DLI.
  • The induction of GVHD and GVL by this approach produced excellent results in patients with CML and modest results in AML, but appeared to be less effective in myeloma and ALL.
  • [MeSH-major] Bone Marrow Transplantation. Granulocyte Colony-Stimulating Factor / therapeutic use. Interferon-alpha / therapeutic use. Leukocyte Transfusion
  • [MeSH-minor] Acute Disease. Adult. Female. Graft vs Host Disease / etiology. Graft vs Leukemia Effect / drug effects. Humans. Leukemia / drug therapy. Leukemia / therapy. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / therapy. Male. Middle Aged. Multiple Myeloma / etiology. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11478351.001).
  • [ISSN] 1444-0903
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Interferon-alpha; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


11. Leda M, Ladon D, Pieczonka A, Boruczkowski D, Jólkowska J, Witt M, Wachowiak J: Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res; 2001 Apr;25(4):353-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
  • A 15-year-old girl with Ph-positive chronic myelogenous leukemia in first chronic phase received bone marrow from her human leukocyte antigen matched brother.
  • Twenty three months after bone marrow transplantation hematological relapse occured which was treated with two infusions of donor lymphocytes (DLI) (0.5x10(8) CD3/kg b.w./infusion).
  • To enforce the graft-versus-leukemia effect (GvL), the first DLI was followed by administration of interferon-alpha (INF-alpha) 6x10(6) U/day for 30 days, whereas, after the second infusion INF-alpha was given at the same dose until hematological remission was achieved (80 doses).
  • Minimal residual disease (MRD) was detected by conventional cytogenetics (Ph chromosome), fluorescence in situ hybridization (FISH) cytogenetics (BCR/ABL translocation) and reverse transcriptase-polymerase chain reaction (RT-PCR) Ecotropic virus integration site-1 (EVI-1 gene expression), whereas cellular chimerism was monitored by assessment of microsatellite markers PCR and Y-chromosomal DNA content FISH.
  • Graft-versus-host disease was not observed at any stage of the treatment.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphocyte Transfusion / methods
  • [MeSH-minor] Adolescent. Antigens, CD3 / blood. Antigens, CD3 / drug effects. Bone Marrow Transplantation / methods. Cyclosporine / administration & dosage. Female. Graft vs Leukemia Effect / drug effects. Humans. Interferon-alpha / administration & dosage. Neoplasm, Residual. Recurrence. Transplantation Chimera. Transplantation, Homologous / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11248334.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Interferon-alpha; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


12. Wassmann B, Scheuring U, Thiede C, Pfeifer H, Bornhäuser M, Griesinger F, Hochhaus A, Schleyer E, Gschaidmeier H, Hoelzer D, Ottmann OG: Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant; 2003 Apr;31(7):611-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
  • We report the response to the ABL kinase inhibitor imatinib mesylate (STI571) in a patient with chronic myeloid leukemia (CML) who relapsed twice after dose-reduced allogeneic stem cell transplantation (alloSCT) for B lymphoid blast crisis (BC) and failed to develop an antileukemic response despite grade 3 graft-versus-host disease (GvHD).
  • Complete hematologic, cytogenetic and molecular responses were achieved within 9 weeks of therapy and are maintained after 27 months.
  • Extensive chronic skin GvHD necessitating immunosuppressive therapy developed after 14 months.
  • This case illustrates the ability of imatinib to induce sustained hematologic and molecular remissions in some patients relapsing with advanced stage CML after alloSCT.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blast Crisis / drug therapy. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692630.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


13. Fischer T: [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia]. Med Klin (Munich); 2002 Jan 15;97 Suppl 1:22-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
  • [Transliterated title] Bisherige Ergebnisse beim Einsatz von STI-571 (Glivec) im Rezidiv nach allogener bzw. autologer Stammzelltransplantation bei CML.
  • BACKGROUND: Gleevec (STI-571) is s selective inhibitor of the bcr/abl tyrosine kinase.
  • Recent phase I and phase II studies in patients with bcr/abl positive CML and ALL showed a low rate of grade III/IV toxicity and good clinical efficacy.
  • This report describes the preliminary results in patients relapsing post autologous or allogeneic peripheral blood stem cell transplantation.
  • THERAPY AND RESULTS: 18 of 18 patients with cytogenetic and/or hematologic relapse in chronic phase CML post autologous stem cell transplantation achieved a complete hematologic remission upon therapy with Gleevec.
  • After allogeneic stem cell transplantation, patients in cytogenetic or hematologic relapse also experienced high hematologic and cytogenetic response rates upon therapy with Gleevec.
  • No symptoms of chronic extensive or > grade I acute GvHD could be observed.
  • Grade III/IV granulocytopenia and/or thrombopenia could be observed in 50% of patients with transformed phases of CML.
  • CONCLUSION: These results show a new approach in treatment of patients with Philadelphia-chromosome-positive leukemia relapsing post autologous or allogeneic stem cell transplantation.
  • The data suggest that early start of STI-571 therapy in MRD-positive patients is a promising approach.
  • Recently, a multicenter phase II study to evaluate the toxicity and efficacy of Gleevec in CML patients with minimal residual disease post allogeneic transplantation was started.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Child. Clinical Trials as Topic. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction. Treatment Outcome


14. Kim YJ, Kim DW, Lee S, Chung NG, Hwang JY, Kim YL, Min CK, Kim CC: Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial. Bone Marrow Transplant; 2004 Mar;33(5):535-42
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
  • Immunotherapy in the form of donor lymphocyte infusions in early-phase relapse might be advantageous as it induces a higher response, but this may be offset by increased toxicity, especially during the early period after transplantation.
  • Among 45 consecutive patients receiving an allograft for CML, 13 patients were diagnosed to have molecular relapse (MRel), as defined by real-time quantitative reverse transcriptase-polymerase chain reaction, and another four patients were diagnosed to have cytogenetic relapse (CRel) within 6 months.
  • Patients with MRel were randomly assigned to either a 'no therapy' group (group A, n=6), in which immunotherapy was reserved until CRel, or an 'immunotherapy' group (group B, n=7).
  • In patients relapsing directly into CRel (n=4), immunotherapy induced MR in two patients (50%).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Neoplasm, Residual / diagnosis. Neoplasm, Residual / therapy. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Benzamides. Combined Modality Therapy. Disease Progression. Female. Graft vs Host Disease / drug therapy. Humans. Imatinib Mesylate. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Piperazines / administration & dosage. Polymerase Chain Reaction. Prospective Studies. Pyrimidines / administration & dosage. Recurrence. Remission Induction. Survival Analysis. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14716340.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Immunosuppressive Agents; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


15. Platzbecker U, Thiede C, Freiberg-Richter J, Helwig A, Mohr B, Prange G, Füssel M, Köhler T, Ehninger G, Bornhäuser M: Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. Ann Hematol; 2001 Mar;80(3):144-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF.
  • Ten patients with high-risk acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS) relapsing early (< 1 year, n = 8) or late (> or = 1 year, n = 2) after allogeneic transplantation were treated with cytoreductive chemotherapy followed by unmanipulated peripheral blood stem cell transplantation (PBSCT) from related (n = 3) and unrelated donors (n = 7).
  • In order to enhance the graft-versus-leukemia effect, patients received no graft-versus-host disease (GVHD) prophylaxis and granulocyte-macrophage colony-stimulating factor (GM-CSF) was given at a dose of 60 micrograms/m2 after transplant.
  • Eight out of ten patients achieved complete remission: one out of two patients with AML and late relapse is in good condition with limited chronic GVHD more than 1 year after the second PBSCT.
  • One patient with blastic phase CML achieved molecular remission but died +330 days after the second PBSCT because of intracranial bleeding.
  • Of the remaining five patients, three died of infectious complications on days +36, +70, and +27, one patient died with extramedullary relapse on day +35, and one from multi-organ failure in association with acute GVHD on day +32 after the second PBSCT.
  • Although several patients achieved complete remission, the high risk of GVHD and treatment-related mortality should be kept in mind, especially when a second transplant is considered during a period of less than 12 months after the first procedure.
  • Monitoring of minimal residual disease might predict relapse thus preventing high doses of cytotoxic drugs for reconditioning.
  • The potential of GM-CSF to enhance the graft-versus-leukemia reactivity after cytoreductive therapy for allogeneic transplantation warrants further investigation.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / therapy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Graft vs Host Disease. Granulocyte-Macrophage Colony-Stimulating Factor. Humans. Karyotyping. Male. Middle Aged. Recurrence. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11320898.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


16. Min CK, Eom KS, Lee S, Kim DW, Lee JW, Min WS, Kim CC: Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients. Bone Marrow Transplant; 2001 May;27(9):999-1005
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
  • In a retrospective single center study, we examined the outcome of induced GVHD in leukemia patients relapsing after allogeneic BMT.
  • Thirty-three adult patients with leukemia (15 AML, 3 ALL, and 15 CML) persisting or relapsing 1-36 months (median, 6) after allogeneic BMT underwent various immune manipulations and consequently developed acute and/or chronic GVHD at our center.
  • Immunotherapies to elicit GVHD comprised chemotherapy followed by PBSC (n = 18), non-myeloablative transplant (n = 2), PBL followed by IFN-alpha (n = 5), PBL alone (n = 3), abrupt cessation of CsA (n = 3), and CsA withdrawal combined with IFN-alpha (n = 2).
  • Twenty-four (72.7%) patients obtained a remission including complete hematological or cytogenetic remission, respectively, for acute leukemias or CML.
  • Twelve (63.2%) of 19 dead patients died due to treatment-related toxicities; five patients from acute GVHD, three from GVHD followed by infections and four from infections.
  • By multivariate Cox analysis, only chronic GVHD resulted in a higher probability of disease-free survival (P = 0.026).
  • Eight patients who had both acute GVHD < or = grade I and chronic GVHD are all alive without leukemia.
  • We conclude that acute GVHD is associated with considerable toxicity while chronic GVHD plays a role in retaining remission in leukemia relapsing after allogeneic BMT.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / etiology. Leukemia / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / toxicity. Cyclosporine / administration & dosage. Cyclosporine / toxicity. Female. Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Hematopoietic Stem Cell Transplantation / mortality. Humans. Immunotherapy / adverse effects. Interferon-alpha / administration & dosage. Interferon-alpha / toxicity. Leukocyte Transfusion / adverse effects. Male. Recurrence. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous / adverse effects. Transplantation, Homologous / mortality


17. Blau IW, Basara N, Bischoff M, Günzelmann S, Römer E, Kirsten D, Schmetzer B, Kiehl MG, Fauser AA: Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant; 2000 Jan;25(1):41-5
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
  • We report 27 patients with relapsed acute or chronic leukemia who underwent a second hematopoietic stem cell transplant (HSCT) from a related or unrelated donor.
  • Seventeen patients were diagnosed with acute myelogenous leukemia (AML), six with acute lymphocytic leukemia (ALL) and four with chronic myeloid leukemia (CML).
  • Relapse was diagnosed between 1 and 45 months after the first HSCT.
  • Sixteen patients who relapsed had received an autologous transplant initially and 11 an allogeneic transplant.
  • Ten patients relapsed within 6 months and 17 patients later than 6 months.
  • Chemotherapy was used as reinduction for relapse after HSCT in 16 patients who had received an autologous transplant and in three who had received an allogeneic transplant, since the latter did not respond to reduction of immunosuppression to induce a graft-versus-leukemia (GVL) reaction.
  • Five of these 19 patients (26%) achieved complete remission (CR), seven patients did not respond to chemotherapy and seven achieved a partial remission (PR).
  • One patient is alive and disease-free after two allogeneic transplants (day +1538), eight patients, who relapsed after an autologous transplant followed by an allogeneic transplant (days +248 to +1140), acute myeloid leukaemia (n = 6) and chronic myeloid leukemia (n = 2) are alive and disease-free.
  • It is suggested that a second HSCT is possible for patients with leukemia relapse following the first autologous transplant.
  • A second transplant might also be offered to patients relapsing after the first allogeneic HSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia / pathology. Leukemia / therapy
  • [MeSH-minor] Acute Disease. Adult. Chronic Disease. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10654013.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


18. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH: Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev; 2005 Nov;19(6):289-300
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
  • Acute lymphoblastic leukaemia (ALL) responds well to chemotherapy and the majority of children and a significant proportion of adults are cured of their disease after primary therapy.
  • However, a number of patients relapse and allogeneic transplantation following conditioning with chemotherapy and radiotherapy offers the possibility of long-term survival in a proportion of these patients.
  • A significant number of patients with ALL develop disease that is refractory to further therapy.
  • The infusion of unmodified donor lymphocytes (DLI) following relapse after allogeneic transplantation has been shown to be curative in patients with chronic myeloid leukaemia (CML).
  • In vivo studies to date suggest that educated T-cells may have a role to play in the treatment of relapsed and refractory ALL in the future.
  • [MeSH-major] Immunotherapy, Adoptive. Lymphocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adult. Child. Child, Preschool. Dendritic Cells / immunology. Dendritic Cells / transplantation. Female. Graft vs Leukemia Effect / immunology. Humans. Male. Neoplasm Proteins / immunology. Secondary Prevention. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / transplantation. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275419.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 89
  •  go-up   go-down


19. Yamada M, Miyamura K, Fujiwara T, Yokoyama H, Tomiya Y, Ishizawa K, Harigae H, Kameoka J, Sasaki T: Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases. Tohoku J Exp Med; 2004 Sep;204(1):79-84
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases.
  • We described here four patients diagnosed with Philadelphia chromosome positive (Ph+) leukemia, consisting of chronic myeloid leukemia (CML) (n=2) and Ph+ acute lymphoblastic leukemia (ALL) (n=2).
  • All patients were treated with imatinib mesylate (300-400 mg/day) for the treatment of relapsed CML after allogeneic hematopoietic stem cell transplantation (SCT) (n=2), relapsed Ph+ ALL after SCT (n=1), and Ph+ ALL preceding SCT (n=1).
  • Notably, serum cyclosporine A concentration increased after the initiation of imatinib treatment, probably through competitive inhibition of P450 3A4 isoenzyme.
  • Our data suggest that imatinib in conjunction with SCT for the Ph+ leukemia may be a promising treatment strategy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Transplantation, Homologous
  • [MeSH-minor] Adult. Benzamides. Cyclosporine / therapeutic use. Enzyme Inhibitors / therapeutic use. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15329466.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 83HN0GTJ6D / Cyclosporine; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


20. Medeiros BC, Chun K, Kamel-Reid S, Lipton J: Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. Am J Hematol; 2007 Aug;82(8):758-60
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
  • Imatinib mesylate (IM) is the standard first-line treatment for patients with chronic myeloid leukemia (CML).
  • Following hematopoietic stem cell transplantation (HSCT), IM induces complete molecular responses (CMR) in approximately 70% patients with relapsed CML, and no IM-related cytogenetic abnormalities in Ph-negative donor-derived cells have been described after HSCT.
  • We report a 56-year-old female who presented with a relapse from CML in September 2002.
  • She had received a matched related HSCT for CML in chronic phase.
  • Donor lymphocyte infusion was given 3 years post-HSCT for a relapse.
  • This observation reinforces the possibility that IM therapy may be casually linked to the phenomenon of secondary cytogenetic changes in diploid cells.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stem Cell Transplantation
  • [MeSH-minor] Adult. Benzamides. Female. Humans. Imatinib Mesylate. Karyotyping. Male. Middle Aged. Philadelphia Chromosome. Recurrence. Tissue Donors. Transplantation, Homologous


21. Agis H, Mannhalter C, Sperr WR, Keil F, Kalhs P, Pirc-Danoewinata H, Krauth MT, Haas OA, Geissler K, Lechner K, Valent P: Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. Leuk Lymphoma; 2004 Jul;45(7):1453-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
  • Recent data suggest that STI571 (Imatinib) induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT).
  • However, little is known about molecular responses to STI571 and the duration of leukemia-free survival in these patients.
  • We report on a 43 year old female patient who presented with a relapse from Ph+ CML in December 2000.
  • At the time of relapse, she presented with marked leukocytosis (89,000 microl) and 10% blasts.
  • In December 2000, therapy with Imatinib was started.
  • Moreover, in response to Imatinib, BCR/ABL transcripts decreased and were no longer detectable after 6 months.
  • After a total observation period of 36 months, the patient is still in complete cytogenetic and molecular remission without signs of occurrence of a donor-type hematopoietic neoplasm or CML relapse.
  • These data suggest that Imatinib is a useful agent for long term treatment of relapsed CML after allogeneic SCT.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Neoplastic Stem Cells / drug effects. Peripheral Blood Stem Cell Transplantation. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Salvage Therapy. Trisomy
  • [MeSH-minor] Adult. Benzamides. Female. Fusion Proteins, bcr-abl / analysis. Humans. Imatinib Mesylate. Karyotyping. Male. Philadelphia Chromosome. Recurrence. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Transplantation Chimera. Transplantation, Homologous


22. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hünerlitürkoglu A, Haas R: Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant; 2001 Jul;28(1):47-9
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
  • Patients with severe aGVHD not responding to treatment with steroids have a poor prognosis.
  • Patients (CML 2, MM 1, AML 1) developed grade III-IV GVHD at a median of 34 days (range 15-76) after myeloablative PBSCT (two), donor lymphocyte infusion for relapsed CML (one) or non-myeloablative PBSCT (one), respectively.
  • All patients had severe intestinal involvement in addition to skin and/or liver disease and had received treatment with high-dose steroids (four) for a median of 11 days (range 5-17) in addition to CsA (four) and MMF (three).
  • At present two patients are alive >200 days after therapy, one with limited cGVHD.
  • Infliximab is apparently an active drug for the treatment of aGVHD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Graft vs Host Disease / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Animals. Anti-Inflammatory Agents / administration & dosage. Female. Hematologic Neoplasms / complications. Hematologic Neoplasms / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Infliximab. Male. Mice. Middle Aged. Recombinant Fusion Proteins / administration & dosage. Salvage Therapy. Steroids / therapeutic use. Transplantation, Homologous / adverse effects. Treatment Outcome. Tumor Necrosis Factor-alpha / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11498743.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Recombinant Fusion Proteins; 0 / Steroids; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


23. Kim YJ, Kim DW, Lee S, Kim YL, Hwang JY, Park YH, Kim HJ, Lee JW, Min WS, Kim CC: Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment. Bone Marrow Transplant; 2004 Jan;33(2):237-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
  • Good prognosis after imatinib mesylate treatment has been reported if cytogenetic clonal evolution (CE) is the only criterion of accelerated phase (AP) chronic myelogenous leukemia (CML).
  • To evaluate the impact of CE upon imatinib treatment in post-transplant settings, responses and toxicities in the relapsed AP-CE were analyzed in comparison with those in the relapsed chronic phase (CP).
  • Nonhematological adverse events were mild and tolerable in both groups and only one (7%) of the 13 patients experienced recurrent graft-versus-host disease after imatinib treatment.
  • Although this is a relatively small group of patients, we suggest that imatinib mesylate should be considered as a front-line treatment for relapsed CML as it showed the high response rate and low toxicity.
  • We also suggest that CE alone is not an important factor in the induction of cytogenetic and molecular remissions in post-transplant relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Clone Cells. Combined Modality Therapy. Female. Graft vs Host Disease / drug therapy. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14628081.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


24. Usuki K, Kanda Y, Iijima K, Iki S, Hirai H, Urabe A: [Chronic myelogenous leukemia in cessation of therapy after sustained CCR with interferon]. Rinsho Ketsueki; 2003 Dec;44(12):1161-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic myelogenous leukemia in cessation of therapy after sustained CCR with interferon].
  • In Ph(+) CML patients who achieved complete cytogenetic response (CCR) with interferon-alpha (IFN) treatment, how long the treatment should be continued has not well been investigated.
  • We report here 2 CML cases who stopped the treatment after CCR had been sustained with IFN for 2-3 years.
  • A 49-year-old male (case 1) achieved CCR 6 months after the initiation of IFN treatment.
  • CCR had been maintained for 3 years, and then the treatment was ceased.
  • CCR has been sustained without any therapy for 4 years.
  • In case 2, a 50-year-old male, CCR was achieved after 8 years of IFN treatment, and maintained for 2 years.
  • One month after cessation of the treatment, CML relapsed cytogenetically.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Cytogenetic Analysis. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14978932.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


25. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, Rezvani K, Craddock C, Rassam S, Prentice HG: Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol; 2001 Dec;115(3):622-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
  • Acute leukaemias in relapse after allogeneic stem cell transplantation (SCT) respond poorly to donor leucocyte infusions (DLI) compared with chronic myeloid leukaemia (CML), at least in part because of faster disease kinetics.
  • Fludarabine-containing 'non-myeloablative' chemotherapy followed by further allo SCT may offer more rapid and effective disease control.
  • We report 14 patients with relapse after allo SCT for acute leukaemia [seven acute myeloid leukaemia (AML), five acute lymphoblastic leukaemia (ALL)] or refractory anaemia with excess blasts in transformation (RAEB-t, n = 2) treated with fludarabine, high-dose cytosine arabinoside (ara-C) and granulocyte colony-simulating factor (G-CSF) with (n = 10) or without (n = 2) idarubicin (FLAG +/- Ida) or DaunoXome (FLAG-X) (n = 2) and second allo SCT from the original donor.
  • Transplants were well tolerated with no treatment-related deaths.
  • The major complication was graft-versus-host disease (GvHD, acute >/= grade II-2 cases, chronic - eight cases, two limited, six extensive) although there have been no deaths attributable to this.
  • FLAG +/- Ida and second allo SCT is a safe and useful approach and may be more effective than DLI in the treatment of acute leukaemias relapsing after conventional allo SCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Cytarabine / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Idarubicin / administration & dosage. Leukemia / therapy. Transplantation Conditioning / methods. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives
  • [MeSH-minor] Acute Disease. Adult. Anemia, Refractory, with Excess of Blasts / therapy. Child. Child, Preschool. Disease-Free Survival. Female. Filgrastim. Graft vs Host Disease / immunology. Graft vs Host Disease / prevention & control. Humans. Leukemia, Myeloid / therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Recombinant Proteins. Recurrence. Reoperation. Retrospective Studies. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11736947.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; PVI5M0M1GW / Filgrastim; ZRP63D75JW / Idarubicin; Ida-FLAG protocol
  •  go-up   go-down


26. Kim PS, Lee PP, Levy D: Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol; 2008 Jun 20;4(6):e1000095
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
  • Recent mathematical models have been developed to study the dynamics of chronic myelogenous leukemia (CML) under imatinib treatment.
  • None of these models incorporates the anti-leukemia immune response.
  • Recent experimental data show that imatinib treatment may promote the development of anti-leukemia immune responses as patients enter remission.
  • Using these experimental data we develop a mathematical model to gain insights into the dynamics and potential impact of the resulting anti-leukemia immune response on CML.
  • The mathematical model suggests that anti-leukemia T cell responses may play a critical role in maintaining CML patients in remission under imatinib therapy.
  • Furthermore, it proposes a novel concept of an "optimal load zone" for leukemic cells in which the anti-leukemia immune response is most effective.
  • Imatinib therapy may drive leukemic cell populations to enter and fall below this optimal load zone too rapidly to sustain the anti-leukemia T cell response.
  • As a potential therapeutic strategy, the model shows that vaccination approaches in combination with imatinib therapy may optimally sustain the anti-leukemia T cell response to potentially eradicate residual leukemic cells for a durable cure of CML.
  • The approach presented in this paper accounts for the role of the anti-leukemia specific immune response in the dynamics of CML.
  • By combining experimental data and mathematical models, we demonstrate that persistence of anti-leukemia T cells even at low levels seems to prevent the leukemia from relapsing (for at least 50 months).
  • As a consequence, we hypothesize that anti-leukemia T cell responses may help maintain remission under imatinib therapy.
  • The mathematical model together with the new experimental data imply that there may be a feasible, low-risk, clinical approach to enhancing the effects of imatinib treatment.
  • [MeSH-major] Immunity, Innate / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Models, Immunological. Piperazines / administration & dosage. Pyrimidines / administration & dosage. T-Lymphocytes / drug effects. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Math Biosci. 2001 Sep;173(1):1-23 [11576559.001]
  • [Cites] Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-5 [16908206.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2633-42 [16981009.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):95-9 [15075898.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):3928-35 [14530309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9714-9 [15980154.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2640-53 [15618470.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] Clin Infect Dis. 1998 Jun;26(6):1290-4 [9636848.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1181-4 [17013383.001]
  • [Cites] PLoS Med. 2007 May;4(5):e176 [17488182.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):993-1009 [11167734.001]
  • [Cites] J Theor Biol. 2005 Sep 7;236(1):39-59 [15967182.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1135-43 [15454486.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3425-32 [15867244.001]
  • [Cites] Blood Rev. 2003 Sep;17(3):153-62 [12818225.001]
  • [Cites] Bone Marrow Transplant. 2001 Oct;28(7):721-4 [11704799.001]
  • [Cites] Cancer Immunol Immunother. 2005 Nov;54(11):1043-58 [15887014.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1399-401 [14534331.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):3-15 [16153857.001]
  • [Cites] J Theor Biol. 2003 Apr 21;221(4):585-98 [12713942.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5342-9 [18326818.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):240-9 [16616071.001]
  • [Cites] Blood. 2002 May 15;99(10):3861-2 [11986250.001]
  • (PMID = 18566683.001).
  • [ISSN] 1553-7358
  • [Journal-full-title] PLoS computational biology
  • [ISO-abbreviation] PLoS Comput. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA130817; United States / NCI NIH HHS / CA / R01CA130817
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC2427197
  •  go-up   go-down


27. Sadiq SA, Rammal M, Sara G: Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS. Mult Scler; 2008 Mar;14(2):272-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
  • We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy.
  • Previously only acute forms of leukemia particularly acute promyelocytic leukemia (APL) have been associated with mitoxantrone treatment in MS.
  • This underscores the need for only using mitoxantrone in severe treatment-unresponsive cases of MS.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced. Mitoxantrone / adverse effects. Multiple Sclerosis, Relapsing-Remitting / drug therapy

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986509.001).
  • [ISSN] 1352-4585
  • [Journal-full-title] Multiple sclerosis (Houndmills, Basingstoke, England)
  • [ISO-abbreviation] Mult. Scler.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


28. Wu HX, Qian SX, Hong M, Zhang YP, Lu H, Zhang R, Zhang XY, Chen LJ, Lu RN, Zhang SJ, Liu P, Ge Z, Fan L, Wang L, Xu J, Tian T, Zhu Y, Qiu HX, Xu W, Sheng RL, Li JY: [Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1330-3
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 75 patients included 35 patients with chronic myeloid leukemia (CML), 30 patients with acute myeloid leukemia, 5 patients with severe aplastic anemia, 3 patients with acute lymphocytic leukemia, one patients with multiple myeloma and one patients with paroxysmal nocturnal hemoglobinuria.
  • Relapsing patients after transplantation received DLI and/or chemotherapy.
  • Patient with CML were treated with imatinib.
  • The median time for the initial hematopoietic reconstitution was 15 (5-25) days.
  • Among 29 dead patients, 9 died of disease relapse, 7 died of III-IV grade of acute GVHD and 7 died of severe infection (2 patients developed interstitial pneumonia).
  • 9 out of 14 patients received haploidentical transplantation were alive, and the time of event-free survival was 30 (6-53) months, the mean survival time of 5 died patients was 7 (2-17) months.
  • It is concluded that allo-PBSCT is effective to treat refractory hematologic diseases, and DLI/or chemotherapy should be used in the patients relapsing after transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099638.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S: High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant; 2000 Aug;26(3):333-8
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
  • Patients with acute leukemias relapsing within 1 year of an allogeneic BMT have a poor prognosis.
  • We studied the use of melphalan 180 mg/m2 followed by allogeneic peripheral blood stem cells (PBSC) as salvage treatment for patients relapsing after related (n = 7) or matched unrelated transplants (n = 3).
  • Diagnoses were AML (n = 4), ALL (n = 3), biphenotypic acute leukemia (n = 2) and CML in blast crisis (n = 1).
  • Eight patients were beyond first relapse and none were in remission.
  • The median time from previous transplant to relapse was 146 days (range 66-206).
  • The median time to an absolute neutrophil count >0.5 x 10(9)/l and to a platelet count >20 x 10(9)/l was 11 and 13 days, respectively.
  • Acute GVHD grades II-III occurred in two subjects, and chronic GVHD in four.
  • Seven patients achieved CR, but relapsed at a median of 116 days (range 56-614).
  • Leukemia was the cause of death in eight patients.
  • This treatment produced responses in the majority of this poor prognosis group.
  • However, durable remissions were not observed, and new treatments to consolidate the responses achieved in this setting are needed.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Melphalan / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adult. Child. Chronic Disease. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Pilot Projects. Remission Induction. Transplantation Chimera


30. Au WY, Lie AK, Ma SK, Wan TS, Liang R, Chan EC, Kwong YL: Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation. Bone Marrow Transplant; 2002 Oct;30(7):453-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.
  • Eight patients with Philadelphia chromosome-positive (Ph(+)) leukaemia relapsing from stem cell transplantation (SCT) (one syngeneic and seven allogeneic) were treated with the tyrosine kinase inhibitor STI571.
  • Five patients relapsing as chronic myeloid leukaemia (CML) in chronic phase achieved a complete haematological response, with complete and major cytogenetic responses occurring in four and one cases, respectively.
  • One patient became negative for BCR/ABL in the bone marrow.
  • Three patients relapsed as acute leukaemia (two CML in myeloblastic crisis and one Ph(+) acute lymphoblastic leukaemia), all of whom achieved haematological and cytogenetic responses.
  • One patient also became BCR/ABL negative.
  • However, pancytopenia and graft-versus-host disease led to cessation of treatment in the remaining two cases, which was followed by disease recurrence refractory to further STI treatment.
  • Our results showed that Ph(+) leukaemic relapses after SCT might respond well to STI571 therapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Benzamides. Drug Evaluation. Female. Fusion Proteins, bcr-abl / genetics. Humans. Imatinib Mesylate. Male. Middle Aged. Myeloablative Agonists. RNA, Neoplasm / analysis. Recurrence. Remission Induction. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12368958.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Myeloablative Agonists; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


31. Elmaagacli AH: Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation. Int J Hematol; 2002 Aug;76 Suppl 2:204-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation.
  • Real-time PCR is a new fluorometric method for cycle-to-cycle quantification of PCR product growth rates.
  • The real-time PCR method is fast and associated with a high reproducibility rate.
  • There are real-time PCR methods for patients with CML, AML and ALL patients with inv(16), t(8;21), t(15;17); t(1;19) and other chromosomal aberrations.
  • For patients with AML monitoring MRD is useful to identify patients who were at high risk for relapse after receiving chemotherapy.
  • In patients with CML monitoring MRD might be helpful to assess success of after allogeneic SCT, or response to therapies with interferon alfa or STI 571.
  • We found, that it is possible to estimate the relapse stage in CML after SCT by the amount of bcr-abl fusion transcript detected using a real-time PCR method.
  • The median measured bcr-abl amount differ significantly (P<0.001) between the various stages, which has relevant clinical implications because it enables early therapeutic decisions in relapsing patients after transplant as e.g. the application of DLI to induce graft-versus-leukemia effects.
  • Using real-time PCR it is possible to detect differences at alleles between recipient and donor at a single nucleotide basis (SNP) for chimerism analysis.
  • The real-time PCR method enables to achieve a high a sensitivity of up to 1x10(-4), which is much more sensitive than all other chimerism methods including VNTR-PCR, STR-PCR.
  • Furthermore, chimerism in male recipients with a female donor can be monitored also by detecting y-chromosome specific sequences by real-time PCR after transplant, which might be the most sensitive method to detect host type gene sequences.
  • All in all, new real-time PCR methods offer a fast, reliable and very sensitive method to evaluate MRD and chimerism in patients after allogeneic SCT and therefore, to help to identify patients who are at high risk for leukemic relapse.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Polymerase Chain Reaction / standards
  • [MeSH-minor] Hematopoietic Stem Cell Transplantation. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Transplantation Chimera. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2002 Jan;116(1):87-93 [11841400.001]
  • [Cites] Blood. 2002 Jan 15;99(2):443-9 [11781223.001]
  • [Cites] Hematology. 2001;5(5):369-381 [11399636.001]
  • [Cites] J Mol Diagn. 2001 Nov;3(4):141-9 [11687597.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):826-30 [11843816.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):1072-5 [11442504.001]
  • [Cites] Eur J Haematol. 2001 Nov-Dec;67(5-6):302-8 [11872078.001]
  • (PMID = 12430926.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


32. Falchi L, Rege-Cambrin G, Fava C, Donti E, Luzi D, Giugliano E, Gubbiotti M, Schippa M, Liberati AM: Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution. Cancer Genet Cytogenet; 2010 Jun;199(2):139-42
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.
  • Little is known regarding the activity of tyrosine kinase inhibitors (TKis) on chronic myeloid leukemia (CML) clonal evolution (CE).
  • We treated 10 CE CML patients in either hematologic chronic (8 cases) or accelerated (2 cases) phase with imatinib or second generation TKi.
  • Additional chromosomal abnormalities appeared during the course of disease in seven cases, being present at diagnosis in three.
  • Major or complete molecular remission (CMR) was obtained in four CCyR patients after 21, 25, 22, and 12 months, as well as in a fifth patient who started nilotinib because of suboptimal response after 75 months of imatinib treatment.
  • One patient received nilotinib due to imatinib intolerance after 56 months of therapy while on CMR, and maintained such status.
  • After a median follow-up of 82 months (range, 3-116), six patients are alive, five of which are in continuous CCyR while one patient is in his third CCyR on dasatinib after relapsing on imatinib and nilotinib.
  • Although a small number of patients was studied, our results suggest that long-term cytogenetic and molecular remission can be achieved in CML CE patients with TKis treatment.
  • [MeSH-major] Clone Cells / drug effects. Clone Cells / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Female. Humans. Imatinib Mesylate. Karyotyping. Male. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471518.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


33. Larghero J, Leguay T, Mourah S, Madelaine-Chambrin I, Taksin AL, Raffoux E, Bastie JN, Degos L, Berthaud P, Marolleau JP, Calvo F, Chomienne C, Mahon FX, Rousselot P: Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol; 2003 Nov 15;66(10):1907-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
  • The Abl tyrosine kinase inhibitor imatinb is becoming a standard for the treatment of chronic myelogenous leukemia (CML).
  • However, Bcr-Abl gene mutations have been reported mainly in relapsing or resistant patients.
  • We aimed to investigate if alpha 1 acid glycoprotein (AGP), an acute phase drug binding protein, could be a biological marker for pharmacological resistance to imatinib in nine patients in acute phase CML.
  • No mutation in the adenosine triphosphate domain of Abl were detected before the initiation of imatinib therapy.
  • By using in vitro tests combining various imatinib concentrations (1-10 microM) with purified human AGP (1 and 3 mg/mL), we demonstrate that imatinib-induced apoptosis of K562 or fresh leukemic CML cells is abrogated or reduced.
  • In patients with CML in blastic phase, AGP levels could reflect pharmacological resistance to imatinib, suggesting that increased dosage of imatinib or the use of a competitor to drug binding should be recommended to optimize the therapeutic effect of the drug.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Blast Crisis / pathology. Drug Resistance, Neoplasm / physiology. Orosomucoid / metabolism. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Apoptosis. Benzamides. Humans. Imatinib Mesylate. K562 Cells. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599548.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Orosomucoid; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


34. Consoli U, Milone G, Guido G, Consoli C, Palumbo GA, Giustolisi R: STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation. Haematologica; 2002 Dec;87(12):ECR37
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Benzamides. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction / methods. Salvage Therapy. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12495908.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down






Advertisement